Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LixiLan vs Insulin Glargine in Japanese T2DM
NCT02752828Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2016
- Primary completion
- Mar 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in HbA1c at 26 weeks. Started May 2016; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02752828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752828.